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Challenges in the development of clinical trials
for major depressive disorder: lessons learned
from trials in minor depression
Mark H. Rapaport, MD; Rachel E. Maddux, BA
ver the last decade, there has been increasing
attention focused on the inadequacy of the current
methodology employed in randomized clinical trials
involving new antidepressant medications.The primary
focus of this concern has centered on the need to ade-
quately differentiate the effectiveness of new treatments
from the placebo condition.There has been considerable
consternation because of the increasing rate of placebo
response seen in all types of trials in psychiatry,particu-
larly trials of mood and anxiety disorders.
1-3This growing
awareness has led to a variety of different efforts that have
begun to address concerns about trial design and method-
ology.
4-6 These include an ongoing series of workshops
sponsored by the National Institute of Mental Health
(NIMH) and the New Clinical Drug Evaluation Unit
(NCDEU).
7 The NIMH has also hosted a series of con-
sensus conferences over the last few years in an attempt to
begin to focus attention on these concerns.Such confer-
ences have investigated issues including placebo and
placebo response and the development of new instru-
ments for the assessment of mood and anxiety disorders.
There has also been a series of international meetings,
including a symposium held in Rhodes,Greece in 2000,
which brought together international experts in method-
ology with senior staff from the NIMH and the Food and
Drug Administration (FDA).The culmination of these
concerted efforts was a consensus statement that was pub-
lished in Neuropsychopharmacology in 2002.
8The Rhodes
panel identified 4 critical problem areas:(i) the nature of
the patient sample;(ii) the limitations of behavioral meth-
ods and analyses used for assessing treatment-related
improvement and recovery; (iii) the lack of consensus
about standards for determining speed of onset and action
for medications;and (iv) the failure to integrate advances
into our knowledge about depression in antidepressant
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This paper reviews some of the challenges faced by indi-
viduals who design and implement clinical trials of poten-
tial antidepressant medications. Particular emphasis is
placed on questioning the validity of some of the theo-
retical assumptions that form the underpinnings of most
conventional trials. Work from our group developing clin-
ical trial methodology for minor depression is used as an
example of how alternate constructs may be helpful to
differentiate drug-placebo differences.
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development with current clinical trial design.The topics
requiring greater emphasis include concerns about the
validity of our current diagnostic nosology,as well as ques-
tions about how diagnoses are made.There are also ques-
tions about the best way to assess the severity of psychi-
atric syndromes. Our current standard is to use
psychometric rating scales. However, many times these
scales only reflect one dimension of a complex illness.
Another critical issue is the number,as well as the length,
of the evaluations to be performed.A related issue of con-
cern is the total length of time that is given to the evalua-
tion of the active treatments.One of the major recurrent
challenges faced in medication development is ensuring
that the trials are adequately powered in order to differ-
entiate relatively subtle differences.Very often power cal-
culations are not based on empirical data, but rather
reflect the aspirations of the trial design planners.
Assumptions made about the sample for the study often
end up greatly influencing the trial design.These assump-
tions are made in order to facilitate the use of relatively
simple inferential statistical models. However, some of
these assumptions reflect lack of thought about the psy-
chiatric syndromes.One of the intrinsic assumptions made
in the design of trials is that the sample being analyzed will
be relatively homogeneous.We frequently attempt to con-
trol for age,ethnicity,length of illness,comorbid diagnosis,
and comorbid medical factors.We frequently do not go to
great lengths to determine that the subjects being evalu-
ated truly have a similar disorder.Yet,any clinician will
readily attest that patients with depression in clinical prac-
tice clearly respond differently to the same medication
and,in some cases,do not respond at all.
9-14This suggests
that there is considerable heterogeneity within the group
of individuals who have major depressive disorder.
Furthermore,clinicians can certainly confirm that the same
medication given to different individuals may produce
very different side-effect profiles for each of those indi-
viduals.Even simple clinical observation suggests that we
are dealing with a heterogeneous syndrome when we dis-
cuss major depressive disorder.An overview of any large
clinical trial’s database will demonstrate that improvement
is not uniform for subjects receiving an active, effective
treatment. Some individuals get markedly better, while
many individuals do not improve at all during a standard
antidepressant trial.
The representativeness of the sample poses another con-
cern. After the advent of the Diagnostic and Statistical
Manual of Mental Disorders, Revised Third Edition, the
concept of comorbidity was given much greater weight.
Prior to that,a hierarchical approach to diagnosis was used.
The emphasis on the presence of comorbid disorders led
to the development of rigorous inclusion and exclusion cri-
teria for most studies.Although there is little empirical evi-
dence that supports the use of most of these inclusion and
exclusion criteria,they have become standardized,and in
many cases,quite limiting.However,it should be noted that
many of these criteria seem to be developed as part of a
response to perceived expectations by regulatory agencies
such as the FDA and the European regulatory authorities.
Nevertheless,these criteria end up limiting the represen-
tativeness of the sample being investigated.The majority
of individuals suffering from the syndrome are excluded
from participation in these trials.Therefore,we have lim-
ited information about the generalizability of either posi-
tive or negative results to the syndrome in general.
A factor that is rarely discussed is the lack of stability
inherent in most of these syndromes.Most clinical trials use
one rating scale as a primary measure of success.Therefore,
the trial measures only a limited aspect of that syndrome.
A second assumption that is made in the design of the trial
and the treatment of the disorder is that the disorder itself
will be relatively stable if no intervention is made.
Unfortunately,this is a fallacious assumption.Some indi-
viduals demonstrate significant week to week variation in
ratings measures, independent of any type of treatment
intervention.This intrinsic fluctuation associated with the
disorder makes it difficult to discern what degree of change
can be attributed to either the placebo condition or the
active treatment condition.This has led to a reductionistic
approach to analysis of subjects and trials, where all
responses and changes are essentially attributed to either
the active treatment condition or the placebo condition.
Lessons learned from clinical trials 
investigating minor depressive disorder
One can use randomized clinical trials in minor depressive
disorder as a case study to emphasize some of the chal-
lenges faced in trial design and possibly some solutions to
these challenges. Minor depressive disorder is an area
where there is no consensus about its conceptualization or
definition.Some individuals believe that minor depression
is merely a segue into major depressive disorder, while
others consider minor depression an entity in itself.
15-17
Some individuals worry that investigating minor depres-
sion trivializes the core concept of major depressive dis-order, while others consider it an important part of the
spectrum of depressive syndromes.
18 Even among those
who believe that minor depression is a valid concept that
requires rigorous investigation, there is considerable
debate about what the definition of minor depression is or
should be.
19 Furthermore,there is little empirical evidence
to support any of the currently employed definitions.
Many of the older clinical trials investigating minor
depression actually grouped patients into cohorts that con-
tained individuals with major depressive disorder
described as being mild in severity.Some of these trials did
not differentiate between major depressive disorder and
a diagnosis of minor depression, but merely stated that
those with lower Hamilton Depression Rating Scale
(HAMD) scores should be considered as having minor
depression. Other trials combined patients with major
depression of a milder form with Research Diagnostic
Criteria (RDC) patients with minor depression.Older tri-
als employed either tricyclic antidepressant medications
or antipsychotic medications.It is not surprising,based on
the side-effect profiles of these agents and the weighting
of the HAMD towards somatic concerns,that it was diffi-
cult to differentiate an active treatment response from a
placebo response.A second challenge that studies of minor
depression emphasize is the use of rating scales that were
developed at another time and for another diagnostic
entity to assess minor depression.All of the older studies
used the HAMD 17 as a primary outcome measure.
20As
discussed above,this rating scale,developed to assess inpa-
tients with endogenous depression, is heavily weighted
toward somatic and/or vegetative factors.This makes the
HAMD a very coarse instrument to use for individuals
with milder forms of depression or minor depression,since
neither somatic nor vegetative symptoms are highly
prominent in such patients.Furthermore,these less highly
prominent symptoms tend to be transient in presentation
and thus may vary greatly from week to week on a rating
scale.This emphasizes the importance of carefully ensur-
ing that the methods of assessment fit the most relevant
signs of the syndrome being studied.Very often,both gov-
ernment and industry have been willing to commit a large
percentage of limited resources to clinical trial research,
without considering the appropriateness of the measures
in assessing the full scope of the syndrome.
Another concern highlighted by investigations of minor
depression is the lack of objective measures of either func-
tional or quality of life impairment.This problem is also
true for most studies of most psychiatric disorders.Thus,in
spite of the fact that the Diagnostic and Statistical Manual
of Mental Disorders,Fourth Edition (DSM-IV) requires
functional impairment or quality of life impairment to be
present in order for a diagnosis of the syndrome to be
made,there have been few efforts to establish some type
of criteria for quality of life or functional impairment with
these disorders.
21 It has been shown in primary care stud-
ies that many people who seem to meet criteria for psy-
chiatric syndromes have spontaneous remissions when fol-
lowed longitudinally.This may well reflect the inclusion of
individuals who, because of life stress, have a particular
series of signs and symptoms,but in actual fact do not have
the pathology associated with a lifelong syndrome. As
would be expected,the result of not paying attention to
these challenges when designing clinical trials is that the
trials tend to be uninformative,if not misleading.
In contrast to some of the problems identified above, a
consortium of investigators at the University of California,
San Diego,the University of Texas Southwestern,Western
Psychiatric Institute and Clinics,and Eli Lilly conducted a
multisite trial of minor depressive disorder (Judd et al,
manuscript submitted).In order to deal with the concerns
about the diagnosis of minor depression,the following cri-
teria were used to operationalize our definition:(i) a sub-
ject had to have dysphoria and anhedonia plus at least one
additional symptom of major depressive disorder from a
DSM-IV checklist, or dysphoria or anhedonia and two
additional symptoms of major depressive disorder;(ii) a
clear-cut functional disability as evidenced by a Global
Assessment of Functioning (GAF) score of less than 70
and Medical Outcome Survey (MOS) subscale score of
less than 75 for social functioning,and of less than 67 for
emotional role functioning.
22,23 In developing these crite-
ria,we recognized that they were rather arbitrary and thus
felt it was necessary to be rigorous and precise with our
definition of what the syndrome was. We deliberately
decided to include individuals with a past history of major
depressive disorder or dysthymia,as long as they had been
in remission for at least 2 years prior to developing their
current episode of minor depression. Furthermore, we
required individuals to have had minor depression for a
minimum of 1 month prior to entering the trial.We delib-
erately did not use a longer period than 1 month,since it
is difficult to gather accurate retrospective information
about the presence of minor symptoms.However,in order
to compensate for concern that our definition of minor
depression was merely a way station for individuals going
into major depressive disorder or recovering from major
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depressive disorder and becoming euthymic,we included
a 4-week,single-blind,placebo lead-in phase to the study.
This caused a second dilemma:which individuals would
we exclude from the study? Since all of the rating scales
we employed were validated for major depressive disor-
der and not minor depression,it was difficult to know how
individuals would score on these measures.Furthermore,
we did not have any data to suggest to us what the range
of symptomatology should be for individuals with minor
depressive disorder on these rating measures.Therefore,
we decided to require that individuals meet the same
entrance requirements for 3 out of 4 weeks in the placebo
phase,including the last 2 weeks prior to randomization,
in order to enter the study.This facilitated getting an accu-
rate sense of the types of changes one would see on the
ratings scales, independent of their having a bearing on
whether or not individuals were able to enter the double-
blind portion of the study.
Some of the other important features of this trial included
the use of the Inventory of Depressive Symptomatology—
Clinician Rated (IDS-C) as well as three different forms
of the HAMD (17-, 21-, and 28-item), the Hamilton
Anxiety Rating Scale,the GAF,and the MOS Short Form
(SF-36).
20,22The IDS-C was identified as the primary out-
come measure because of the unique features of the scale.
First, this scale encompasses a much broader range of
depressive symptomatology,extending from various psy-
chological symptoms through somatic symptoms.Second,
this symptom scale attempts to quantify,in a uniform way,
both the severity and the intensity of symptomatology.Yet,
we were not comfortable merely using existing rating
scales as a way of assessing response in this trial.Therefore,
we also investigated the effects of active treatment on
complete resolution of symptoms of depression,plus res-
olution of functioning.This is a remarkably high bar to
attempt to overcome.
Another crucial feature,as described earlier in this arti-
cle,is the length of the evaluation.Many early random-
ized clinical trials were 2- to 4-week placebo-controlled
trials.
23 Over time,trials have extended to 6 to 8 weeks’
duration.Yet, as is clearly emphasized by the work of
Stassen and colleagues and others,many individuals with
major depressive disorder are just beginning to reach
recovery at the 8- to 12-week time points.
24Therefore,we
elected a 12-week acute trial particularly because we
were interested in determining the number of individu-
als that met remission criteria,as well as a change in rat-
ing scale.The primary input,again,was the change in the
IDS-C with the major outcome point being the ability to
achieve complete remission for 1 month prior to the end
of the trial.
Since we were dealing with minor depression,it created a
series of opportunities that we felt we had to explore in
order to gather pilot data if further investigations were
warranted. One of the other major questions was: what
happens if one allows individuals to undergo an extended
period of time on placebo (ie,4 months)? Will this impact
response to pharmacotherapy? A second question was:is
acute treatment of minor depression sufficient? Will indi-
viduals who respond acutely require continuation treat-
ment, as is the case with major depressive disorder?
Additionally, what is the course of untreated minor
depression for individuals who participate in a trial? Are
we placing these people at an increased risk or burden by
their continued presence in the trial while on placebo? In
order to gather pilot data to begin to answer these ques-
tions,individuals who completed the initial 12 weeks of the
trial entered a continuation phase.The randomization of
individuals for the acute and continuation phase of the
trial were performed at the initial point of randomization,
rather than a second re-randomization,after completion
of the acute trial.Therefore,individuals in this trial were
randomized both to an acute phase and maintenance
treatment with either fluoxetine or placebo and to one of
four continuation phase conditions:fluoxetine-fluoxetine,
fluoxetine-placebo,placebo-placebo,or placebo-fluoxe-
tine.Analysis of the continuation phase of the study was a
priori specified to be exploratory,because we knew that
sizes of the cells would not be sufficient to answer these
questions.
There were several features during the analysis plan that
were unique.First was the realization that minor depres-
sion was most likely a heterogeneous syndrome.
Therefore,we acknowledged the need to investigate the
relationship between minor depression and a previous his-
tory of major depressive disorder and dysthymia,and also
the relationship between minor depression and a family
history of psychiatric disorders. In an attempt to more
thoroughly utilize the data that would be gathered in this
study,we decided that a mixed regression model would be
more powerful than a standard analysis of variance of sta-
tistical approach.However,since the random regression
model is not as accepted in psychiatric literature,we spec-
ified in the initial data analysis plan that both types of
analyses be performed.A third aspect of this study was the
evaluation of the categorical end point (ie,full remissionof symptoms and return of functioning), as well as the
parametric end points.
One can use the design of this trial in minor depression to
address a number of the challenges that we had earlier
identified.This trial is a good example of the type of con-
sensus thinking process that can be used to enhance 
diagnostic rigor and assessment of severity of illness.
Furthermore,it highlights the need to carefully review the
items within assessment instruments,in order to ensure
that the instruments are as useful as possible for the dis-
order.This study also highlights the type of thought that
should go into determining the evaluation for a study.
Since minor depression was an unknown entity at the
time, one of the key questions was: how stable is this
entity over time? Although 4 weeks is an arbitrary length
of time, we felt for ethical and scientific reasons, that it
would be an adequate length of time for an extended
placebo run-in.
Conclusions
A careful and critical review of clinical trial methodolo-
gies is imperative for the field to move forward.Attention
to many of the assumptions that are inclusively made
when a trial is designed will be critical in enhancing the
success of clinical trials.We must think closely about the
diagnostic criteria used in the trial in the inclusion and
exclusion criteria.Many of the currently accepted criteria
limit the generalizability of the findings and have not been
demonstrated in a systematic fashion to enhance differ-
entiation of drug versus placebo responses. Yet, some
important aspects of the very definition of these syn-
dromes have been neglected,in particular,the importance
of including functional disability and quality of life dys-
function as part of the definition of the syndrome.Some
individuals may present with a requisite number of symp-
toms,but may not be as adversely affected as if they had
had a profound,long-lasting syndrome.It is quite likely
they are suffering from a transient constellation of symp-
toms due to an external stressor.A second important con-
cern is the appropriateness of the assessments that are
being used in randomized controlled trials.Very often,the
assessments that are employed represent “me too”assess-
ments, because studies done by other companies have
used the measures in the past.Yet,this may not reflect our
best knowledge about the disorder being studied,nor a
sufficient way of bringing a new compound onto the mar-
ket.Frequently,the argument for the use of such instru-
ments is that they are supposedly mandated by regulatory
agencies. However, more often than not, this is a myth
that is perpetuated rather than the outcome of frank and
careful discussions with the regulatory authority.A third
important issue that requires some thought is assumptions
about the stability of the syndrome over time.Many times,
studies are designed with the assumption that random-
ization to placebo should lead to a relatively static or,if
anything,disadvantageous course for patients.Yet,inves-
tigation of most medical syndromes suggests that there is
an intrinsic waxing and waning to the course of the syn-
drome.Therefore,arbitrary assessment using instruments
that investigate only one aspect of the syndrome may well
lead to spurious results.
A last concern,but one that can greatly influence a trial,
involves appropriate statistical design.Often studies are
powered based on desire,rather than available data.A sec-
ond concern is that often a new statistical design repre-
sents the easiest or safest design,rather than a design that
is most likely to produce informative results.
In conclusion,it is clear that there is tremendous oppor-
tunity to improve the design and methodology used in ran-
domized clinical trials.The recognition of these challenges
by the NIMH,the FDA,the European regulatory author-
ities, as well as industry, implies that important future
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Desafíos en el desarrollo de ensayos clínicos
para el trastorno depresivo mayor: lecciones
aprendidas de los ensayos en la depresión
menor
Este artículo revisa algunos de los desafíos que
afrontan aquellos investigadores que trabajan en
el diseño y la realización de ensayos clínicos con
medicamentos con potencial antidepresivo. Se cues-
tiona con especial énfasis la validez de algunos de
los supuestos teóricos que forman las bases de los
ensayos más convencionales. Se utiliza el trabajo de
nuestro grupo que desarrolla metodología de ensa-
yos clínicos para la depresión menor como un ejem-
plo de cómo los constructos alternativos pueden ser
útiles para distinguir las diferencias fármaco-pla-
cebo.
Défis posés par le développement des 
essais cliniques sur les troubles dépressifs
majeurs : leçons tirées des essais sur les
dépressions légères
Cet article passe en revue quelques-uns des défis
lancés à ceux qui conçoivent et réalisent des essais
cliniques pour évaluer l’efficacité de nouveaux
médicaments antidépresseurs. Il a été particulière-
ment insisté sur la mise en question de la validité
de quelques-unes des hypothèses théoriques qui
étayent la plupart des essais classiques. Le travail de
notre groupe qui développe une méthodologie
d’essai clinique pour les dépressions légères illustre
comment l’utilisation de concepts différents peut
permettre de distinguer les différences médica-
ment-placebo.